Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder

Eligibility Criteria

• * Between age 25 and 75.
• * Current DSM-5 diagnosis of moderate to severe AUD (≥4 diagnostic symptoms).
• * Able to attend scheduled clinic visits
• * Able to read, understand and voluntarily sign Informed Consent prior to participating in any study-specific procedures or assessments.
• * If on a medication regimen, that regimen will be stable for the duration of the study;
• * Fluency in English.
• * Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) contraindications: such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, metal in the head, metal in the body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device/objected in the head and body within 30 cm of the treatment coil.
• * General medical condition, disease or neurological disorder that interferes with the assessments or participation.
• * Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk.
• * Current substance abuse (except caffeine or nicotine) as determined by positive toxicology screen.
• * Have a mass lesion, cerebral infarct, or other active CNS disease, including an alcohol-related seizure or a seizure disorder. • A recent suicide attempt (defined as within the last 30 days) or presence of current suicidal plan or intent. Patients at risk for suicide will be required to establish a written safety plan involving their primary therapist before entering the study.
• * Severe impediment to vision, hearing and/or hand movement, likely to interfere with the ability to follow study protocols. • Greater than mild traumatic brain injury (defined as greater than 10 minutes loss of consciousness).
• * Taking benzodiazepine or neuroleptic medications, or any medication known to alter seizure threshold
• * unstable chronic illness.
• * Current or lifetime history of bipolar disorder or psychosis.
• * Participation in another concurrent intervention based clinical trial.